AlbertKoongMDFASTRO

Radiation Oncology • Houston, TX

Associate Professor, Radiation Oncology, Stanford University Medical Center

Join to view full profile

Dr. Koong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Koong's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

Stanford Health Care-Sponsored Stanford UniversityResidency, Radiation Oncology, 1997 - 2001
Kaiser Permanente Northern California (Oakland)Internship, Internal Medicine, 1996 - 1997
Northwestern University The Feinberg School of MedicineClass of 1996

Certifications & Licensure

FL State Medical License 2021 - Present
CA State Medical License 1997 - 2027
TX State Medical License 2017 - 2026
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Evaluation of Stereotactic Radiosurgery For Liver Malignancies Start of enrollment: 2003 Oct 01
Completed
Phase 1
Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer Start of enrollment: 2003 Jul 01
Completed
Phase 2
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy Start of enrollment: 2002 Jan 01
Recruiting
Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer Start of enrollment: 2006 Apr 01
Completed
Phase 2
Metabolic Imaging Predict Histopathologic Response to Preop ChemoXRT for Locally Advanced Rectal CA Start of enrollment: 2003 Oct 01
Terminated
Not Applicable
Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx Start of enrollment: 2006 Oct 01
Completed
Not Applicable
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma Start of enrollment: 2009 Oct 01
Completed
Phase 2
Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers Start of enrollment: 2010 Aug 01
Completed
Phase 1
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies Start of enrollment: 2010 Sep 01
Terminated
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2008 Dec 01
Completed
Phase 1
Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC) Start of enrollment: 2011 Feb 01
Withdrawn
Phase 3
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma Start of enrollment: 2011 Feb 01
Withdrawn
Phase 3
Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer Start of enrollment: 2012 Feb 24
Completed
Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer Start of enrollment: 2013 Aug 14
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Institution-Wide Retreats Foster Organizational Learning and Action at a Comprehensive Cancer Center.
Benjamin R Schrank, John A Fuller, Colleen M Gallagher, Van K Morris, Emma B Holliday
Journal of Cancer Education. 2024-08-01
Optimizing Outpatient Radiation Oncology Consult Workflow by Using Time-Driven Activity-Based Costing: Efficiency and Financial Impacts.
Julius Weng, Shane Mesko, Gregory Chronowski, Percy Lee, Seungtaek Choi
JCO Oncology Practice. 2024-05-01
3 citations
Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells.
DaeYong Lee, Kristin Huntoon, Yifan Wang, Minjeong Kang, Yifei Lu
Nature Biomedical Engineering. 2024-05-01

Journal Articles

Development of Deep Neural Network for Individualized Hepatobiliary Toxicity Prediction After Liver SBRT
Daniel Chang, Albert Koong, Medical Physics
Germline Cancer Susceptibility Gene Variants, Somatic Second Hits, and Survival Outcomes in Patients with Resected Pancreatic Cancer
Richard F Dunne, Leona A Doyle, William C Hahn, Jason L Hornick, Andrea J Bullock, Sapna Syngal, Albert C Koong, Natalia Khalaf, Brian M Wolpin, Douglas A Rubinson, Da..., Nature
Strategies for Prediction and Mitigation of Radiation-Induced Liver Toxicity
Daniel T Chang, Albert C Koong, Journal of Radiation Research

Press Mentions

The Cancer Letter’s Most-Read Stories of 2024December 13th, 2024
Pancreatic Cancer Treatment at MD Anderson Gave Me HopeNovember 29th, 2022
The Radiosurgery Society® Announces the Newest Members of Its RSS Sponsorship AllianceApril 29th, 2020
Join now to see all

Grant Support

Targeting Galectin-1 With Radiation In Lung CancerNational Cancer Institute2012
Pharmacological Targeting Of The Unfolded Protein Response As An Antitumor StrateNational Cancer Institute2009–2011
Pharmacologic /Genetic Inhibition Of XBP1 As Hypoxia Targeted Therapeutic StrategNational Cancer Institute2007–2011
The Role Of XBP1 During Hypoxia And Tumor GrowthNational Cancer Institute2005–2008